DEA Considers Bulk Manufacturing of Psilocybin for Science

2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment

Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.

2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas

The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.

2026-11572 — Ashley Vermillion, N.P.; Decision and Order

Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.

2026-11416 — Importer of Controlled Substances Application: CalCog Inc.

CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.

2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I

The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.

2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I

Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.

Previous: 2025-21789 — Proposed Information Collection Activity; ACF Performance Progress Report, ACF-OGM-SF-PPR-B

The Administration for Children and Families wants to keep using their Performance Progress Report form for three more years but with fewer questions to make it easier for grantees to fill out. This affects groups like state and local governments, tribes, nonprofits, and universities who get ACF grants. Comments on these changes are open until February 2, 2026, helping save time without cutting funding decisions.

Next: 2025-21793 — Carbon and Certain Alloy Steel Wire Rod From China; Revised Schedule for the Subject Proceeding

The U.S. International Trade Commission is updating the timeline for reviewing carbon and certain alloy steel wire rod from China because of a government shutdown delay. Companies involved should note that the staff report is now out on November 19, 2025, and comments are due by November 26, 2025. This change could affect trade decisions and any related duties or tariffs.